This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

'First-in-man' Implant Of Regenerative Cell Therapy In Parkinson's Disease

SYDNEY and AUCKLAND, New Zealand, Sept. 19, 2013 /PRNewswire/ -- Living Cell Technologies Limited (LCT) today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL(R) – a potential treatment for Parkinson's disease.

The pioneering brain surgery was conducted at Auckland City Hospital and the patient has recovered well so far. An MRI scan taken the day after the surgery indicated that the NTCELL capsules have been implanted at their intended target. The patient and family have requested privacy and no contact with the media.

The Phase I clinical trial is an open label investigation of the safety and clinical effect of NTCELL in four people who have been diagnosed with Parkinson's disease for at least four years. The first patient will now be monitored for two months to confirm no serious adverse safety events. At that time, the independent data safety monitoring board (DSMB) will consider the safety data and advise if the implants for the remaining three patients can proceed.

The trial Principal Investigator is Dr Barry Snow (MBChB, FRACP, FRCPC), an internationally recognised clinician and researcher in Parkinson's disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board. "The team are pleased with how well the patient tolerated the procedure itself," says Dr Snow. "The surgery is relatively straightforward in neurosurgery terms, and we have taken full advantage of well-established techniques, which lowers the clinical risk. The patient will now be monitored closely by the team over the next two months."

Dr Andrea Grant, CEO and Managing Director of LCT says: "This is a significant milestone and a world first. It has taken a great deal of hard work, clinical and scientific endeavour to get to this and so of course we are excited. The purpose of this "first-in-man" study is to demonstrate the treatment is safe.  Provided this trial is succesful, future trials will further assess the extent of clinical benefit that patients might gain."

In the clinical trial, NTCELL is injected under guidance by neuroimaging into the affected area of the human brain where substantial death of neurons and other cells has occurred. The cell therapy is comprised of choroid plexus cells, which are naturally occurring 'support' cells for the brain. LCT's propriety technology IMMUPEL(R) coats the implanted cells to protect them from attack by the patient's immune system.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs